U.S. markets open in 9 minutes
  • S&P Futures

    3,906.50
    -16.00 (-0.41%)
     
  • Dow Futures

    31,899.00
    -17.00 (-0.05%)
     
  • Nasdaq Futures

    13,177.75
    -124.25 (-0.93%)
     
  • Russell 2000 Futures

    2,280.90
    -4.20 (-0.18%)
     
  • Crude Oil

    62.68
    -0.54 (-0.85%)
     
  • Gold

    1,780.70
    -17.20 (-0.96%)
     
  • Silver

    27.83
    -0.10 (-0.35%)
     
  • EUR/USD

    1.2220
    +0.0052 (+0.43%)
     
  • 10-Yr Bond

    1.4530
    +0.0640 (+4.61%)
     
  • Vix

    22.72
    -0.39 (-1.69%)
     
  • GBP/USD

    1.4143
    +0.0002 (+0.02%)
     
  • USD/JPY

    106.1620
    +0.2800 (+0.26%)
     
  • BTC-USD

    51,412.25
    +1,489.01 (+2.98%)
     
  • CMC Crypto 200

    1,027.76
    +12.84 (+1.27%)
     
  • FTSE 100

    6,680.64
    +21.67 (+0.33%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Bio-Rad Laboratories: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 72.84% year over year to $4.01, which beat the estimate of $3.29.

Revenue of $789,839,000 up by 26.49% from the same period last year, which beat the estimate of $686,800,000.

Looking Ahead

Bio-Rad Sees FY21 Adj. Currency-Neutral Sales Growth 4.5-5% Year Over Year

Details Of The Call

Date: Feb 11, 2021

Time: 06:00 PM

View more earnings on BIO

ET Webcast URL: https://edge.media-server.com/mmc/p/8cfv55c7

Technicals

52-week high: $648.39

Company's 52-week low was at $309.38

Price action over last quarter: Up 9.79%

Company Overview

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.